Professor Simon Dixon BSc (Southampton), MSc (York), PhD (Sheffield)
Professor of Health Economics
The University of Sheffield
Regent Court, 30 Regent Street
Sheffield, S1 4DA
Direct telephone: (+44) (0)114 222 0724
General office fax: (+44) (0)114 222 0749
My work at ScHARR has concentrated around undertaking and developing methods for economic evaluations alongside controlled trials. Whilst the main focus of this work has been pre-hospital and emergency care, I have undertaken evaluations in numerous other areas. A separate stream of work is examining the measurement and valuation of health care benefits. This is focusing on alternatives to, and extensions of, the standard QALY model.
- Public preferences for public health (link to project page under 'Projects').
- Use of attitudinal information in willingness to pay surveys.
- Measurement and valuation of health care benefits.
- Economic evaluation.
My teaching is concentrated around the methods of economic evaluation which I teaching in various formats on the MSc Health Economics and Decision Modelling, MSc Economics and Health Economics, MSc International Health Technology Assessment, Pricing and Reimbursement and the MBChB.
I am the module coordinator for the Economic Evaluation modules on MSc International Health Technology Assessment, Pricing and Reimbursement.
I am interested in supervising Research Students wishing to develop the methods of economic evaluation and benefit valuation. I am particularly interested in empirical ethics and a more empirically based QALY approach, including the role of sequences and process utility.
I currently supervise, or sit on the supervisory panel for three students; Victoria Brennan, Kinga Lowrie and Sabine Grimm. Their topics relate to the evaluation of an electronic patient questionnaire, evaluation of telehealth and the valuation of innovation in non-pharmaceutical technologies.
- Director Health Economics and Decision Science (HEDS)
- Member of the National Institute for Health and Clinical Excellence (NICE) Technology Appraisal Committee
- Trial Steering Group member for a number of studies
- Advisory Board for HERU, University of Aberdeen
- Development of a questionnaire and social tariff for dignity in health care and the general population
- Evaluating cost effectiveness of insulin pumps in type 1 diabetes as part of a RCT
- Replacing conventional spine radiographs with dual energy x-ray absorptiometry in children with suspected reduction in bone density: a cost-effectiveness analysis
- Economic evaluation of dementia service redesign across Leeds
- Assessing the potential cost-effectiveness of a long-acting growth hormone antagonist for treatment in acromegaly
- Whyte S, Dixon S, Faria R, Walker S, Palmer S, Sculpher M & Radford S (2016) Estimating the Cost-Effectiveness of Implementation: Is Sufficient Evidence Available?. Value in Health, 19(2), 138-144. View this article in WRRO
- Rowen D, Dixon S, Hernández-Alava M & Mukuria C (2016) Estimating informal care inputs associated with EQ-5D for use in economic evaluation. The European Journal of Health Economics, 17(6), 733-744. View this article in WRRO
- Everard ML, Hind D, Ugonna K, Freeman J, Bradburn M, Dixon S, Maguire C, Cantrill H, Alexander J, Lenney W, McNamara P, Elphick H, Chetcuti PAJ, Moya EF, Powell C, Garside JP, Chadha LK, Kurian M, Lehal RS, MacFarlane PI, Cooper CL & Cross E (2015) Saline in Acute Bronchiolitis RCT and Economic evaluation: hypertonic saline in acute bronchiolitis – randomised controlled trial and systematic review. Health Technology Assessment, 19(66), 1-130. View this article in WRRO
- Thokala P, Dixon S & Jahn B (2015) Resource Modelling: The Missing Piece of the HTA Jigsaw?. PharmacoEconomics, 33(3), 193-203.
- Tosh J, Dixon S, Carter A, Daley A, Petty J, Roalfe A, Sharrack B & Saxton JM (2014) Cost effectiveness of a pragmatic exercise intervention (EXIMS) for people with multiple sclerosis: economic evaluation of a randomised controlled trial.. Mult Scler, 20(8), 1123-1130.
- Shackley P & Dixon S (2013) The random card sort method and respondent certainty in contingent valuation: An exploratory investigation of range bias. Health Economics (United Kingdom).
- Brennan VK & Dixon S (2013) Incorporating process utility into quality adjusted life years: a systematic review of empirical studies.. Pharmacoeconomics, 31(8), 677-691.
- Dixon S, Shackley P, Bonham J & Ibbotson R (2012) Putting a value on the avoidance of false positive results when screening for inherited metabolic disease in the newborn.. J Inherit Metab Dis, 35(1), 169-176.
- Dixon S, Poole CD, Odeyemi I, Retsa P, Chambers C & Currie CJ (2011) Deriving health state utilities for the numerical pain rating scale.. Health Qual Life Outcomes, 9, 96.
- Gillett M, Dallosso HM, Dixon S, Brennan A, Carey ME, Campbell MJ, Heller S, Khunti K, Skinner TC & Davies MJ (2010) Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis.. BMJ, 341, c4093.